The medical device CRO market is projected to grow at an annualized rate of 6.4%, till 2030 !

Roots Analysis has done a detailed study on “Medical Device CRO Market (2nd Edition), 2020-2030”. covering various important aspects of the industry and identifying key future growth opportunities.

To order this 400+ page report, which features 240+ figures and 200+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html

Key Market Insights
 Since 2015, over 7,500 medical device focused clinical trials, involving the participation of close to 2.9 million patients across different hospitals / medical centers, have been registered worldwide
 Over 300 CROs presently claim to possess the necessary capabilities to offer a wide range of preclinical and clinical research-related services to medical device-focused business entities
 The market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of such firms are located in the developed geographies
 Owing to the high competition in this field, stakeholders are steadily expanding their capabilities in order to augment their respective service portfolios and also comply to evolving industry benchmarks
 Over the years, the domain has witnessed an increase in merger and acquisition activity, with many CROs expanding their presence across multiple geographies and growing their respective service portfolios
 Several companies in this domain have established strong brand positions across different regions; in future, such companies are anticipated to contribute the most to the overall revenue generation potential
 Driven by the growing demand for effective treatment modalities across various therapeutic areas, the market is poised to witness sustained growth across various device classes and geographies
 In the long term, we expect the market to reach over USD 15 billion; the current and future opportunity is likely to be distributed across companies of different sizes offering various types of clinical and preclinical services

For more information, please visit https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Medical Devices
3.2.1. Historical Evolution of Medical Devices
3.2.2. Classification of Medical Devices
3.3. Overview of Contract Research Organizations (CROs)
3.3.1. Evolution of CROs
3.4. Role of CROs in the Medical Device Industry

3.5. Types of Medical Device CROs
3.6. Types of Services Offered by CROs
3.7. Advantages of Outsourcing Operations to CROs
3.8. Risks and Challenges Associated with Outsourcing
3.9. Key Considerations for Selecting a Suitable CRO Partner

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Medical Device CROs: Clinical Service Providers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Area of Specialization
4.2.6. Analysis by Device Class
4.2.7. Analysis by Type of Clinical Operation Services Offered
4.2.8. Analysis by Type of Regulatory Affairs-related Services Offered
4.2.9. Analysis by Type of Additional Services Offered
4.2.10. Analysis by Medical Device Regulatory Compliance Authorities

4.3. Medical Device CROs: Preclinical Service Providers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Analysis by Type of Preclinical Services Offered

4.4. Medical Device CROs: Standalone Service Providers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Company Size and Location of Headquarters

5. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
5.1. Chapter Overview
5.2. General Regulatory and Reimbursement Guidelines for Medical Devices

5.3. Regulatory and Reimbursement Landscape in North America
5.3.1. The US Scenario
5.3.1.1. Regulatory Authority
5.3.1.2. Review / Approval Process
5.3.1.3. Reimbursement Landscape
5.3.1.3.1. Payer Mix
5.3.1.3.2. Reimbursement Process

5.3.2. The Canadian Scenario
5.3.2.1. Regulatory Authority
5.3.2.2. Review / Approval Process
5.3.2.3. Reimbursement Landscape
5.3.2.3.1. Payer Mix
5.3.2.3.2. Reimbursement Process

5.3.3. The Mexican Scenario
5.3.3.1. Regulatory Authority
5.3.3.2. Review / Approval Process
5.3.3.3. Reimbursement Landscape
5.3.3.3.1. Payer Mix

5.4. Regulatory and Reimbursement Landscape in Europe
5.4.1. Overall Scenario
5.4.1.1. Overall Regulatory Authority
5.4.1.2. Overall Review / Approval Process

5.4.2. The UK Scenario
5.4.2.1. Regulatory Authority
5.4.2.2. Review / Approval Process
5.4.2.3. Reimbursement Landscape
5.4.2.3.1. Payer Mix
5.4.2.3.2. Reimbursement Process

5.4.3. The French Scenario
5.4.3.1. Regulatory Authority
5.4.3.2. Review / Approval Process
5.4.3.3. Reimbursement Landscape
5.4.3.3.1. Payer Mix
5.4.3.3.2. Reimbursement Process

5.4.4. The German Scenario
5.4.4.1. Regulatory Authority
5.4.4.2. Review / Approval Process
5.4.4.3. Reimbursement Landscape
5.4.4.3.1. Payer Mix
5.4.4.3.2. Reimbursement Process

5.4.5. The Italian Scenario
5.4.5.1. Regulatory Authority
5.4.5.2. Review / Approval Process
5.4.5.3. Reimbursement Landscape
5.4.5.3.1. Payer Mix
5.4.5.3.2. Reimbursement Process

5.4.6. The Spanish Scenario
5.4.6.1. Regulatory Authority
5.4.6.2. Review / Approval Process
5.4.6.3. Reimbursement Landscape
5.4.6.3.1. Payer Mix
5.4.6.3.2. Reimbursement Process

5.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
5.5.1. The Australian Scenario
5.5.1.1. Regulatory Authority
5.5.1.2. Review / Approval Process
5.5.1.3. Reimbursement Landscape
5.5.1.3.1. Payer Mix
5.5.1.3.2. Reimbursement Process

5.5.2. The Brazilian Scenario
5.5.2.1. Regulatory Authority
5.5.2.2. Review / Approval Process
5.5.2.3. Reimbursement Landscape
5.5.2.3.1. Payer Mix
5.5.2.3.2. Reimbursement Process

5.5.3. The Chinese Scenario
5.5.3.1. Regulatory Authority
5.5.3.2. Review / Approval Process
5.5.3.3. Reimbursement Landscape
5.5.3.3.1. Payer Mix
5.5.3.3.2. Reimbursement Process

5.5.4. The Indian Scenario
5.5.4.1. Regulatory Authority
5.5.4.2. Review / Approval Process
5.5.4.3. Reimbursement Landscape
5.5.4.3.1. Payer Mix

5.5.5. The Israeli Scenario
5.5.5.1. Regulatory Authority
5.5.5.2. Review / Approval Process
5.5.5.3. Reimbursement Landscape
5.5.5.3.1. Payer Mix

5.5.6. The Japanese Scenario
5.5.6.1. Regulatory Authority
5.5.6.2. Review / Approval Process
5.5.6.3. Reimbursement Landscape
5.5.6.3.1. Payer Mix
5.5.6.3.2. Reimbursement Process

5.5.7. The New Zealand Scenario
5.5.7.1. Regulatory Authority
5.5.7.2. Review / Approval Process
5.5.7.3. Reimbursement Landscape
5.5.7.3.1. Payer Mix
5.5.7.3.2. Reimbursement Process

5.5.8. The Singapore Scenario
5.5.8.1. Regulatory Authority
5.5.8.2. Review / Approval Process
5.5.8.3. Reimbursement Landscape
5.5.8.3.1. Payer Mix
5.5.8.3.2. Reimbursement Process

5.5.9. The South Korean Scenario
5.5.9.1. Regulatory Authority
5.5.9.2. Review / Approval Process
5.5.9.3. Reimbursement Landscape
5.5.9.3.1. Payer Mix
5.5.9.3.2. Reimbursement Process

5.5.10. The South African Scenario
5.5.10.1. Regulatory Authority
5.5.10.2. Review / Approval Process
5.5.10.3. Reimbursement Landscape

5.5.11. The Taiwan Scenario
5.5.11.1. Regulatory Authority
5.5.11.2. Review / Approval Process
5.5.11.3. Reimbursement Landscape
5.5.11.3.1. Payer Mix
5.5.11.3.2. Reimbursement Process

5.5.12. The Thailand Scenario
5.5.12.1. Regulatory Authority
5.5.12.2. Review / Approval Process
5.5.12.3. Reimbursement Landscape

5.6. Comparison of Regional Regulatory Control
5.7. Concluding Remarks

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Avania (Formerly known as Factory CRO)
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Future Outlook

6.3. Charles River Laboratories
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Future Outlook

6.4. Clinlogix
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Future Outlook

6.5. CROMSOURCE
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Future Outlook

6.6. CSSi LifeSciences
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Future Outlook

6.7. Eurofins Medical device Testing
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Future Outlook

6.8. genae
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Future Outlook

6.9. IMARC Research
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Future Outlook

6.10. IQVIA
6.10.1. Company Overview
6.10.2. Service Portfolio
6.10.3. Future Outlook

6.11. Medpace
6.11.1. Company Overview
6.11.2. Service Portfolio
6.11.3. Future Outlook

6.12. NAMSA
6.12.1. Company Overview
6.12.2. Service Portfolio
6.12.3. Future Outlook

6.13. Qserve Group
6.13.1. Company Overview
6.13.2. Service Portfolio
6.13.3. Future Outlook

6.14. Regulatory and Clinical Research Institute (Now a part of Covance)
6.14.1. Company Overview
6.14.2. Service Portfolio
6.14.3. Future Outlook

6.15. WuXi AppTec
6.15.1. Company Overview
6.15.2. Service Portfolio
6.15.3. Future Outlook

7. MEDICAL DEVICE DEVELOPER AND CRO RELATIONSHIPS: KEY VALUE DRIVERS AND PERFORMANCE INDICATORS
7.1. Chapter Overview
7.2. Definition and Importance of Key Performance Indicators (KPIs)
7.3. Key Considerations for Selection of KPIs
7.4. Types of KPIs
7.4.1. Financial Indicators
7.4.1.1. Most Important KPIs
7.4.1.1.1. Financial Stability
7.4.1.1.2. Cost of Services Offered
7.4.1.1.3. Comparative Analysis of Financial Indicators

7.4.1.2. Industry Perspective
7.4.1.2.1. Sponsors’ (Big Pharma) Perspective
7.4.1.2.2. Contract Service Providers’ Perspective

7.4.2. Process and Capability Indicators
7.4.2.1. Most Important KPIs
7.4.2.1.1. Proximity to Sponsor
7.4.2.1.2. Capability to Innovate / Mitigate Risk
7.4.2.1.3. Strength of Service Portfolio
7.4.2.1.4. Comparative Analysis of Process / Capability Indicators

7.4.2.2. Industry Perspective
7.4.2.2.1. Sponsors’ (Big Pharma) Perspective
7.4.2.2.2. Contract Service Providers’ Perspective

7.4.3. Market Reputation Indicators
7.4.3.1. Most Important KPIs
7.4.3.1.1. Flexibility / Adaptability
7.4.3.1.2. Time Management
7.4.3.1.3. Quality / Reliability
7.4.3.1.4. Regulatory Compliance / Track Record
7.4.3.1.5. Comparative Analysis of Market Reputation Indicators

7.4.3.2. Industry Perspective
7.4.3.2.1. Sponsors’ (Big Pharma) Perspective
7.4.3.2.2. Contract Service Providers’ Perspective

7.5. Comparison of Key Performance Indicators
7.6. Concluding Remarks

8. COMPETITIVE BENCHMARKING
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Competitive Benchmarking by Region
8.3.1. North America, Peer Group I
8.3.2. North America, Peer Group II
8.3.3. North America, Peer Group III
8.3.4. Europe, Peer Group IV
8.3.5. Europe, Peer Group V
8.3.6. Europe, Peer Group VI
8.3.7. Asia-Pacific, Peer Group VII
8.3.8. Asia-Pacific, Peer Group VIII
8.3.9. RoW, Peer Group IX
8.4. Concluding Remarks

9. BRAND POSITIONING OF KEY INDUSTRY PLAYERS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Brand Positioning Matrix: Labcorp
9.4. Brand Positioning Matrix: IQVIA
9.5. Brand Positioning Matrix: Syneos Health
9.6. Brand Positioning Matrix: PPD
9.7. Brand Positioning Matrix: ICON
9.8. Brand Positioning Matrix: Charles River Laboratories
9.9. Brand Positioning Matrix: WuXi AppTec
9.10. Brand Positioning Matrix: Medpace
9.11. Brand Positioning Matrix: PAREXEL International
9.12. Brand Positioning Matrix: NAMSA

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Medical Devices: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Therapeutic Area
10.3.5. Analysis by Geography
10.3.6. Geographical Analysis by Trial Status
10.4. Analysis by Type of Sponsor

10.5. Medical Devices: Analysis of Enrolled Patient Population
10.5.1. Analysis by Trial Registration Year
10.5.2. Analysis by Trial Status
10.5.3. Analysis by Trial Phase
10.5.4. Analysis by Therapeutic Area
10.5.5. Analysis by Location of Trial Site
10.5.6. Analysis by Trial Status and Location of Trial Site

11. MERGERS AND ACQUISITIONS
11.1. Chapter Overview
11.2. Merger and Acquisition Models
11.3. Medical Device CROs: Mergers and Acquisitions
11.3.1. Analysis by Year of Merger / Acquisition
11.3.2. Analysis by Type of Agreement
11.3.3. Regional Analysis
11.3.3.1. Continent-wise Distribution
11.3.3.2. Intercontinental and Intracontinental Deals
11.3.3.3. Country-wise Distribution

11.3.4. Ownership Change Matrix
11.3.5. Analysis by Type of Company
11.3.6. Analysis by Key Value Drivers
11.3.6.1. Analysis by Key Value Drivers and Year of Acquisition

12. SURVEY INSIGHTS
12.1. Chapter Overview
12.2. Designation of Respondents
12.3. Type of Service Offered
12.4. Target Therapeutic Area
12.5. Number of Annual Projects
12.6. Market Opportunity

13. MARKET SIZING AND FORECAST
13.1. Chapter Overview
13.2. Assumptions and Forecast Methodology

13.3. Overall Medical Device CRO Market, 2020-2030
13.3.1. Medical Device CRO Market, 2020-2030: Distribution by Therapeutic Area
13.3.2. Medical Device CRO Market, 2020-2030: Distribution by Scale of Operation
13.3.3. Medical Device CRO Market, 2020-2030: Distribution by Device Class
13.3.4. Medical Device CRO Market, 2020-2030: Distribution by Type of Clinical Service Offered
13.3.5. Medical Device CRO Market, 2020-2030: Distribution by Type of Preclinical Service Offered
13.3.6. Medical Device CRO Market, 2020-2030: Distribution by Geography

13.4. Medical Device CRO Market in North America, 2020-2030
13.4.1. Medical Device CRO Market in North America, 2020-2030: Distribution by Therapeutic Area
13.4.1.1. Medical Device CRO Market for CNS Disorders in North America, 2020-2030
13.4.1.2. Medical Device CRO Market for Cardiovascular Disorders in North America, 2020-2030
13.4.1.3. Medical Device CRO Market for Oncological Disorders in North America, 2020-2030
13.4.1.4. Medical Device CRO Market for Bone Disorders in North America, 2020-2030
13.4.1.5. Medical Device CRO Market for Respiratory Disorders in North America, 2020-2030
13.4.1.6. Medical Device CRO Market for Pain Management Disorders in North America, 2020- 2030
13.4.1.7. Medical Device CRO Market for Ophthalmic Disorders in North America, 2020-2030
13.4.1.8. Medical Device CRO Market for Psychological Disorders in North America, 2020-2030
13.4.1.9. Medical Device CRO Market for Metabolic Disorders in North America, 2020-2030
13.4.1.10. Medical Device CRO Market for Other Therapeutic Areas in North America, 2020-2030

13.4.2. Medical Device CRO Market in North America, 2020-2030: Distribution by Device Class
13.4.2.1. Medical Device CRO Market for Class I Devices in North America, 2020-2030
13.4.2.2. Medical Device CRO Market for Class II Devices in North America, 2020-2030
13.4.2.3. Medical Device CRO Market for Class III Devices in North America, 2020-2030

13.4.3. Medical Device CRO Market in North America, 2020-2030: Distribution by Type of Clinical Service Offered
13.4.3.1. Medical Device CRO Market for Clinical Trial Management Services in North America, 2020-2030
13.4.3.2. Medical Device CRO Market for Consulting Services in North America, 2020-2030
13.4.3.3. Medical Device CRO Market for Data Management Services in North America, 2020-2030
13.4.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in North America, 2020-2030
13.4.3.5. Medical Device CRO Market for Other Clinical Services in North America, 2020-2030

13.4.4. Medical Device CRO Market in North America, 2020-2030: Distribution by Type of Preclinical Service Offered
13.4.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in North America, 2020-2030
13.4.4.2. Medical Device CRO Market for Biocompatibility Testing Services in North America, 2020-2030
13.4.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in North America, 2020-2030
13.4.4.4. Medical Device CRO Market for Other Preclinical Services in North America, 2020- 2030

13.5. Medical Device CRO Market in Europe, 2020-2030
13.5.1. Medical Device CRO Market in Europe, 2020-2030: Distribution by Therapeutic Area
13.5.1.1. Medical Device CRO Market for CNS Disorders in Europe, 2020-2030
13.5.1.2. Medical Device CRO Market for Cardiovascular Disorders in Europe, 2020-2030
13.5.1.3. Medical Device CRO Market for Oncological Disorders in Europe, 2020-2030
13.5.1.4. Medical Device CRO Market for Bone Disorders in Europe, 2020-2030
13.5.1.5. Medical Device CRO Market for Respiratory Disorders in Europe, 2020-2030
13.5.1.6. Medical Device CRO Market for Pain Management Disorders in Europe, 2020-2030
13.5.1.7. Medical Device CRO Market for Ophthalmic Disorders in Europe, 2020-2030
13.5.1.8. Medical Device CRO Market for Psychological Disorders in Europe, 2020-2030
13.5.1.9. Medical Device CRO Market for Metabolic Disorders in Europe, 2020-2030
13.5.1.10. Medical Device CRO Market for Other Therapeutic Areas in Europe, 2020-2030

13.5.2. Medical Device CRO Market in Europe, 2020-2030: Distribution by Device Class
13.5.2.1. Medical Device CRO Market for Class I Devices in Europe, 2020-2030
13.5.2.2. Medical Device CRO Market for Class II Devices in Europe, 2020-2030
13.5.2.3. Medical Device CRO Market for Class III Devices in Europe, 2020-2030

13.5.3. Medical Device CRO Market in Europe, 2020-2030: Distribution by Type of Clinical Service Offered
13.5.3.1. Medical Device CRO Market for Clinical Trial Management Services in Europe, 2020-2030
13.5.3.2. Medical Device CRO Market for Consulting Services in Europe, 2020-2030
13.5.3.3. Medical Device CRO Market for Data Management Services in Europe, 2020-2030
13.5.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in Europe, 2020-2030
13.5.3.5. Medical Device CRO Market for Other Clinical Services in Europe, 2020-2030

13.5.4. Medical Device CRO Market in Europe, 2020-2030: Distribution by Type of Preclinical Service Offered
13.5.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in Europe, 2020-2030
13.5.4.2. Medical Device CRO Market for Biocompatibility Testing Services in Europe, 2020-2030
13.5.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in Europe, 2020-2030
13.5.4.4. Medical Device CRO Market for Other Preclinical Services in Europe, 2020-2030

13.6. Medical Device CRO Market in Asia-Pacific, 2020-2030
13.6.1. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Therapeutic Area
13.6.1.1. Medical Device CRO Market for CNS Disorders in Asia-Pacific, 2020-2030
13.6.1.2. Medical Device CRO Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030
13.6.1.3. Medical Device CRO Market for Oncological Disorders in Asia-Pacific, 2020-2030
13.6.1.4. Medical Device CRO Market for Bone Disorders in Asia-Pacific, 2020-2030
13.6.1.5. Medical Device CRO Market for Respiratory Disorders in Asia-Pacific, 2020-2030
13.6.1.6. Medical Device CRO Market for Pain Management Disorders in Asia-Pacific, 2020-2030
13.6.1.7. Medical Device CRO Market for Ophthalmic Disorders in Asia-Pacific, 2020-2030
13.6.1.8. Medical Device CRO Market for Psychological Disorders in Asia-Pacific, 2020-2030
13.6.1.9. Medical Device CRO Market for Metabolic Disorders in Asia-Pacific, 2020-2030
13.6.1.10. Medical Device CRO Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030

13.6.2. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Device Class
13.6.2.1. Medical Device CRO Market for Class I Devices in Asia-Pacific, 2020-2030
13.6.2.2. Medical Device CRO Market for Class II Devices in Asia-Pacific, 2020-2030
13.6.2.3. Medical Device CRO Market for Class III Devices in Asia-Pacific, 2020-2030

13.6.3. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Type of Clinical Service Offered
13.6.3.1. Medical Device CRO Market for Clinical Trial Management Services in Asia-Pacific, 2020-2030
13.6.3.2. Medical Device CRO Market for Consulting Services in Asia-Pacific, 2020-2030
13.6.3.3. Medical Device CRO Market for Data Management Services in Asia-Pacific, 2020-2030
13.6.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in Asia-Pacific, 2020-2030
13.6.3.5. Medical Device CRO Market for Other Clinical Services in Asia-Pacific, 2020-2030

13.6.4. Medical Device CRO Market in Asia-Pacific, 2020-2030: Distribution by Type of Preclinical Service Offered
13.6.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in Asia-Pacific, 2020-2030
13.6.4.2. Medical Device CRO Market for Biocompatibility Testing Services in Asia-Pacific, 2020- 2030
13.6.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in Asia- Pacific, 2020-2030
13.6.4.4. Medical Device CRO Market for Other Preclinical Services in Asia-Pacific, 2020-2030

13.7. Medical Device CRO Market in Rest of the World, 2020-2030
13.7.1. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Therapeutic Area
13.7.1.1. Medical Device CRO Market for CNS Disorders in Rest of the World, 2020-2030
13.7.1.2. Medical Device CRO Market for Cardiovascular Disorders in Rest of the World, 2020-2030
13.7.1.3. Medical Device CRO Market for Oncological Disorders in Rest of the World, 2020-2030
13.7.1.4. Medical Device CRO Market for Bone Disorders in Rest of the World, 2020-2030
13.7.1.5. Medical Device CRO Market for Respiratory Disorders in Rest of the World, 2020-2030
13.7.1.6. Medical Device CRO Market for Pain Management Disorders in Rest of the World, 2020-2030
13.7.1.7. Medical Device CRO Market for Ophthalmic Disorders in Rest of the World, 2020-2030
13.7.1.8. Medical Device CRO Market for Psychological Disorders in Rest of the World, 2020-2030
13.7.1.9. Medical Device CRO Market for Metabolic Disorders in Rest of the World, 2020-2030
13.7.1.10. Medical Device CRO Market for Other Therapeutic Areas in Rest of the World, 2020-2030

13.7.2. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Device Class
13.7.2.1. Medical Device CRO Market for Class I Devices in Rest of the World, 2020-2030
13.7.2.2. Medical Device CRO Market for Class II Devices in Rest of the World, 2020-2030
13.7.2.3. Medical Device CRO Market for Class III Devices in Rest of the World, 2020-2030

13.7.3. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Type of Clinical Service Offered
13.7.3.1. Medical Device CRO Market for Clinical Trial Management Services in Rest of the World, 2020-2030
13.7.3.2. Medical Device CRO Market for Consulting Services in Rest of the World, 2020-2030
13.7.3.3. Medical Device CRO Market for Data Management Services in Rest of the World, 2020-2030
13.7.3.4. Medical Device CRO Market for Regulatory Affairs Management Services in Rest of the World, 2020-2030
13.7.3.5. Medical Device CRO Market for Other Clinical Services in Rest of the World, 2020- 2030

13.7.4. Medical Device CRO Market in Rest of the World, 2020-2030: Distribution by Type of Preclinical Service Offered
13.7.4.1. Medical Device CRO Market for Material Characterization and Analytical Services in Rest of the World, 2020-2030
13.7.4.2. Medical Device CRO Market for Biocompatibility Testing Services in Rest of the World, 2020-2030
13.7.4.3. Medical Device CRO Market for Sterility and Microbiology Testing Services in Rest of the World, 2020-2030
13.7.4.4. Medical Device CRO Market for Other Preclinical Services in Rest of the World, 2020-2030

14. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
14.1. Chapter Overview
14.2. Impact of Coronavirus Upsurge on Medical Device Industry
14.3. Future Strategies and Action Plans: A Bird’s Eye View

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Concluding Remarks

16. FUTURE TRENDS AND OPPORTUNITIES
16.1. Chapter Overview
16.2. Anticipated Growth in Number of Connected Devices
16.3. Adoption of Data Analytics and Real-Time Monitoring Solutions
16.4. Need for Cloud-based Computing and Storage Solutions
16.5. Growing Need for Real World Evidence for Regulatory Approval
16.6. Concluding Remarks

17. INTERVIEW TRANSCRIPTS
17.1. Chapter Overview
17.2. Lajos Sarosi, Chief Executive Officer and Co-founder, HungaroTrial
17.3. Christopher Rupp, Vice President of Global Marketing and Commercial Operations, NAMSA
17.4. Christian Wolflehner, General Manager, CW Research & Management
17.5. Troy McCall, Chief Operating Officer, CROMSOURCE
17.6. Nazish Urooj, Senior manager, Medical & Clinical Operations, Metrics Research
17.7. C. Omprakash, Technical Director and Partner, Vyomus Consulting
17.8. Tania Persson, Director of Business Development, A+ Science
17.9. Alexa Foltin-Mertgen, Business Development Manager, AtoZ-CRO

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com